Clinical trial
The Impact of Rosiglitazone on Regression of Atherosclerosis
NCT00166803 · National Taiwan University Hospital, Other · Suspended
Key facts
| NCT number | NCT00166803 |
|---|---|
| Title | The Impact of Rosiglitazone on Regression of Atherosclerosis |
| Official title | The Impact of Rosiglitazone on Regression of Atherosclerosis: A Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Study |
| Lead sponsor | National Taiwan University Hospital, Other |
| Collaborators | National Science and Technology Council, Taiwan |
| Status | Suspended |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Atherosclerosis |
| Intervention type | Drug |
| Interventions | Rosiglitazone |
| Enrollment | 60 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2008 |
| First posted | Sep 14, 2005 |
| Last update posted | Jan 5, 2009 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: